A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Baricitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RA-BUILD
- Sponsors Eli Lilly and Company
- 27 Oct 2021 Results (n=3770) assessing safety of baricitinib for the treatment of rheumatoid arthritis from long-term extension study and integrated database (NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT02265705, NCT01721044, NCT01721057, NCT01711359 and NCT01885078), published in the Annals of the Rheumatic Diseases.
- 15 Jun 2019 Results of pooled analysis from nine studies of Baricitinib treated rheumatoid arthritis patients presented at the 20th Annual Congress of the European League Against Rheumatism
- 06 Jun 2019 According to an Eli Lilly media release, data from this trial will be presented at the upcoming Annual European Congress of Rheumatology (EULAR 2019) in Madrid from June 12-15, 2019.